Searched for
CIPLA LTD MD
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...
- Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividendCipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Cipla global CEO Umang Vohra to step down; Achin Gupta to take overCipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from ...
- Reports of likely promoter stake sale making people anxious: Cipla MD Vohra"We're all human beings, we get distracted with what happens, because of this and that distraction creates difficulties for us in the way w...
- Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...
- Cipla board approves reappointment of Umang Vohra as MD & Global CEO for 5 yearsThe board of directors has considered and approved the re-appointment of Umang Vohra, Managing Director, designated as 'Managing Director a...
- Cipla launches generic remdesivir for coronavirus patientsThe USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of coron...
- Cipla ties up with Roche to sell 2 cancer drugs in IndiaThe pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.
- Cipla bags Rs 1,100 crore order from South African governmentCipla Medpro, the SA subsidiary of the Indian firm, has bagged the order as part of the South African government's 2015-17 National ARV ten...
- Cipla shares end nearly 4% higher post agreement with Serum InstituteCipla's stock surged 3.23 per cent to settle at Rs 618.60 on the BSE. In intra-day, it climbed 4.13 per cent to Rs 624.
- Cipla Ltd to market Serum Institute's paediatric vaccines in EuropeCipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.
- Sell Cipla with target price of Rs 402: Sandeep WagleSell Cipla with stoploss of Rs 421 and for target of Rs 402.
- Buy Cipla Ltd with target price of Rs 440: Sandeep WagleCipla Ltd is a 'BUY' call with a target of Rs 440 and a stop loss of Rs 406.
- Buy Cipla with target of Rs 406: Sandeep Wagle"Buy Cipla with a stop loss of Rs 384 and a target price of Rs 406".
- Sell Cipla with target of 310: Sandeep WagleSell Cipla in the range of 322 to 325 with stop loss of 327.50 and a target of 310.
- Roche sues Cipla over Valcyte patent breachSwiss major Roche has moved the Bombay High Court (HC) against domestic major Cipla for allegedly infringing both the patent and trademark ...
Load More
